Expert Ratings for Genmab
Portfolio Pulse from Benzinga Insights
Genmab (NASDAQ:GMAB) has received 8 bullish and 5 somewhat bearish ratings from analysts in the last quarter. The average 12-month price target for the stock, according to 13 analysts, is $44.23, a 34.03% increase from the previous average price target of $33.00.
September 26, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Genmab has received a mix of bullish and somewhat bearish ratings from analysts, with an increased average 12-month price target.
The mixed analyst ratings indicate uncertainty about the stock's performance. However, the increased average 12-month price target suggests that analysts see potential for growth in the stock's price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100